These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
300 related articles for article (PubMed ID: 28720686)
1. Oncolytic virus-induced cell death and immunity: a match made in heaven? De Munck J; Binks A; McNeish IA; Aerts JL J Leukoc Biol; 2017 Sep; 102(3):631-643. PubMed ID: 28720686 [TBL] [Abstract][Full Text] [Related]
2. Critical Interactions between Immunogenic Cancer Cell Death, Oncolytic Viruses, and the Immune System Define the Rational Design of Combination Immunotherapies. van Vloten JP; Workenhe ST; Wootton SK; Mossman KL; Bridle BW J Immunol; 2018 Jan; 200(2):450-458. PubMed ID: 29311387 [TBL] [Abstract][Full Text] [Related]
4. Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment. Shi T; Song X; Wang Y; Liu F; Wei J Front Immunol; 2020; 11():683. PubMed ID: 32411132 [TBL] [Abstract][Full Text] [Related]
5. Oncolytic virotherapy as promising immunotherapy against cancer: mechanisms of resistance to oncolytic viruses. Goradel NH; Alizadeh A; Hosseinzadeh S; Taghipour M; Ghesmati Z; Arashkia A; Negahdari B Future Oncol; 2022 Jan; 18(2):245-259. PubMed ID: 34821517 [TBL] [Abstract][Full Text] [Related]
6. Oncolytic Virotherapy: A New Paradigm in Cancer Immunotherapy. Volovat SR; Scripcariu DV; Vasilache IA; Stolniceanu CR; Volovat C; Augustin IG; Volovat CC; Ostafe MR; Andreea-Voichița SG; Bejusca-Vieriu T; Lungulescu CV; Sur D; Boboc D Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256250 [TBL] [Abstract][Full Text] [Related]
7. Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance. Schirrmacher V Expert Opin Biol Ther; 2015; 15(12):1757-71. PubMed ID: 26436571 [TBL] [Abstract][Full Text] [Related]
8. The discovery and development of oncolytic viruses: are they the future of cancer immunotherapy? Zhang S; Rabkin SD Expert Opin Drug Discov; 2021 Apr; 16(4):391-410. PubMed ID: 33232188 [No Abstract] [Full Text] [Related]
9. Arming oncolytic viruses to leverage antitumor immunity. de Gruijl TD; Janssen AB; van Beusechem VW Expert Opin Biol Ther; 2015 Jul; 15(7):959-71. PubMed ID: 25959450 [TBL] [Abstract][Full Text] [Related]
10. Oncolytic Viral Therapy and the Immune System: A Double-Edged Sword Against Cancer. Marelli G; Howells A; Lemoine NR; Wang Y Front Immunol; 2018; 9():866. PubMed ID: 29755464 [TBL] [Abstract][Full Text] [Related]
11. Oncolytic virotherapy and immunogenic cancer cell death: sharpening the sword for improved cancer treatment strategies. Workenhe ST; Mossman KL Mol Ther; 2014 Feb; 22(2):251-256. PubMed ID: 24048442 [TBL] [Abstract][Full Text] [Related]
12. A review exploring the fusion of oncolytic viruses and cancer immunotherapy: An innovative strategy in the realm of cancer treatment. Chattopadhyay S; Hazra R; Mallick A; Gayen S; Roy S Biochim Biophys Acta Rev Cancer; 2024 Jul; 1879(4):189110. PubMed ID: 38754793 [TBL] [Abstract][Full Text] [Related]
13. Oncolytic ImmunoViroTherapy: A long history of crosstalk between viruses and immune system for cancer treatment. Feola S; Russo S; Ylösmäki E; Cerullo V Pharmacol Ther; 2022 Aug; 236():108103. PubMed ID: 34954301 [TBL] [Abstract][Full Text] [Related]